 CAMBRIDGE, Mass., Jan. 4, 2022 PRNewswire -- Nuvalent, Inc. Nasdaq: NUVL, a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D. 